Efficacy and safety of adding once-weekly dulaglutide to basal insulin for inadequately controlled type 2 diabetes in Chinese patients (AWARD-CHN3): A randomized, double-blind, placebo-controlled, phase III trial.
Diabetes, obesity & metabolism（2023）
摘要
Dulaglutide added to basal insulin was efficacious and well tolerated in Chinese patients with T2DM.
更多查看译文
关键词
basal insulin, Chinese, dulaglutide, GLP-1 receptor agonists, type 2 diabetes
AI 理解论文
溯源树
样例
生成溯源树，研究论文发展脉络
Chat Paper
正在生成论文摘要